Results 101 to 110 of about 22,026 (263)

New treatments in the management of type 2 diabetes: a critical appraisal of saxagliptin

Diabetes, Metabolic Syndrome and Obesity, 2010
Baptist GallwitzDept Medicine IV, Tübingen University, Otfried-Müller-Str, 10, 72076 Tübingen, GermanyAbstract: Saxagliptin is a novel dipeptidyl peptidase-4 inhibitor (DPP-4 inhibitor) for the treatment of type 2 diabetes, with a duration
Gallwitz B
doaj   +2 more sources

The treatment of type 2 diabetes in the presence of renal impairment: what we should know about newer therapies

Clinical Pharmacology: Advances and Applications, 2016
Melanie Davies,1,2 Sudesna Chatterjee,1,2 Kamlesh Khunti1,2 1Diabetes Research Centre, University of Leicester, 2Leicester Diabetes Centre, University Hospitals of Leicester NHS Trust, Leicester, UK Abstract: Worldwide, an estimated 200 million people ...
Davies M, Chatterjee S, Khunti K
doaj  

Purification and Identification of Novel Dipeptidyl Peptidase IV Inhibitory Peptides Derived from Bighead Carp (Hypophthalmichthys nobilis)

Foods
Dipeptidyl peptidase IV (DPP-IV) inhibitors are widely used in treating type 2 diabetes due to their ability to lower blood glucose levels. However, synthetic versions often lead to gastrointestinal side effects.
Hanzhi Zheng, Leyan Zhao, Yushuo Xie, Yuqing Tan   +3 more
doaj   +1 more source

Mechanism of Action of Natural Dipeptidyl Peptidase-IV Inhibitors (Berberine and Mangiferin) in Experimentally Induced Diabetes with Metabolic Syndrome. [PDF]

Int J Appl Basic Med Res, 2023
Suman RK, Borde MK, Mohanty IR, Singh HK.   +3 more
europepmc   +1 more source

A Dipeptidyl Peptidase-4 Inhibitor, Des-Fluoro-Sitagliptin, Improves Endothelial Function and Reduces Atherosclerotic Lesion Formation in Apolipoprotein E–Deficient Mice [PDF]

, 2005
ObjectivesThe aim of this study was to investigate the antiatherogenic effects of the dipeptidyl peptidase-4 inhibitor, des-fluoro-sitagliptin (DFS).BackgroundThe new class of anti–type 2 diabetes drugs, dipeptidyl peptidase-4 inhibitors, improves ...
Matsubara, Junichi, Sugiyama, Seigo, Sugamura, Koichi, Nakamura, Taishi, Fujiwara, Yukio, Akiyama, Eiichi, Kurokawa, Hirofumi, Nozaki, Toshimitsu, Ohba, Keisuke, Konishi, Masaaki, Maeda, Hirofumi, Izumiya, Yasuhiro, Kaikita, Koichi, Sumida, Hitoshi, Jinnouchi, Hideaki, Matsui, Kunihiko, Kim-Mitsuyama, Shokei, Takeya, Motohiro, Ogawa, Hisao   +18 more
core   +1 more source

Sexual Safety Signals of Common Antidiabetic Drugs: Insights From FAERS Disproportionality Analysis

Andrology, EarlyView.
ABSTRACT Background Erectile dysfunction is a prevalent and distressing complication of diabetes mellitus that markedly affects quality of life in male patients. Although the role of diabetes in erectile dysfunction is well‐established, potential drug‐induced sexual dysfunction associated with commonly prescribed antidiabetic medications remains ...
Shan Lin, Xuefeng Ding, Xin Dang, Qingyuan Zhan   +3 more
wiley   +1 more source

Direct cardiovascular effects of glucagon like peptide-1 [PDF]

, 2013
Current gold standard therapeutic strategies for T2DM target insulin resistance or β cell dysfunction as their core mechanisms of action. However, the use of traditional anti-diabetic drugs, in most cases, does not significantly reduce macrovascular ...
Asfandyar Sheikh
core   +1 more source

SGLT2 inhibitors and mortality in older adults with diabetic kidney disease: A target trial emulation study. [PDF]

Diabetes Obes Metab
Abstract Aims Randomized controlled trials on sodium‐glucose cotransporter 2 (SGLT2) inhibitors have yielded inconsistent findings regarding mortality benefits. It remains unclear whether, and in which subgroups, SGLT2 inhibitors confer survival benefits in older adults with diabetic kidney disease (DKD).
Azegami T, Kaneko H, Okada A, Suzuki Y, Ko T, Aoyama K, Nakayama T, Kimura Y, Fujiu K, Takeda N, Morita H, Yokoo T, Node K, Nangaku M, Takeda N, Yasunaga H, Hayashi K.   +16 more
europepmc   +2 more sources

Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review

British Journal of Pharmacology, EarlyView.
Abstract In the 2025 novel drug mini‐review, one can take a full measure of the ingenuity that underlies current drug design and development, despite the year's smaller harvest (46 novel drugs) compared to 2024 (53) and 2023 (70). 54% of the novel drugs are first‐in‐class (FIC).
Andreas Papapetropoulos, Stavros Topouzis, Steve P. H. Alexander, Miriam M. Cortese‐Krott, Zsuzsanna Helyes, Kirill Martemyanov, Claudio Mauro, Nithyanandan Nagercoil, Reynold A. Panettieri Jr, Hemal H. Patel, Rainer Schulz, Barbara Stefanska, Gary J. Stephens, Nathalie Vergnolle, Xin Wang, Stephen Ward, Péter Ferdinandy   +16 more
wiley   +1 more source

Heterocyclic Compounds as Dipeptidyl Peptidase-IV Inhibitors with Special Emphasis on Oxadiazoles as Potent Anti-Diabetic Agents. [PDF]

Molecules, 2022
Mohammad BD, Baig MS, Bhandari N, Siddiqui FA, Khan SL, Ahmad Z, Khan FS, Tagde P, Jeandet P.   +8 more
europepmc   +1 more source